{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:40:16Z","timestamp":1792651216340,"version":"4.5.0"},"reference-count":77,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"unspecified","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,4,14]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICI) can lead to long-term responses in patients with metastatic melanoma. Still many patients with melanoma are intrinsically resistant or acquire secondary resistance. Previous studies have used primary or metastatic tumor tissue for biomarker assessment. Especially in melanoma, metastatic lesions are often present at different anatomical sites such as skin, lymph nodes, and visceral organs. The anatomical site may directly affect the tumor microenvironment (TME). To evaluate the impact of tumor evolution on the TME and on ICI treatment outcome, we directly compared paired primary and metastatic melanoma lesions for tumor mutational burden (TMB), HLA-ABC status, and tumor infiltrating lymphocytes (TILs) of patients that received ipilimumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>TMB was analyzed by sequencing primary and metastatic melanoma lesions using the TruSight Oncology 500 assay. Tumor tissues were subjected to multiplex immunohistochemistry to assess HLA-ABC status and for the detection of TIL subsets (B cells, cytotoxic T cells, helper T cells, and regulatory T cells), by using a machine-learning algorithm.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>While we observed a very good agreement between TMB of matched primary and metastatic melanoma lesions (intraclass coefficient=0.921), such association was absent for HLA-ABC status, TIL density, and subsets thereof. Interestingly, analyses of different metastatic melanoma lesions within a single patient revealed that TIL density and composition agreed remarkably well, rejecting the hypothesis that the TME of different anatomical sites affects TIL infiltration. Similarly, the HLA-ABC status between different metastatic lesions within patients was also comparable. Furthermore, high TMB, of either primary or metastatic melanoma tissue, directly correlated with response to ipilimumab, whereas lymphocyte density or composition did not. Loss of HLA-ABC in the metastatic lesion correlated to a shorter progression-free survival on ipilimumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We confirm the link between TMB and HLA-ABC status and the response to ipilimumab-based immunotherapy in melanoma, but no correlation was found for TIL density, neither in primary nor metastatic lesions. Our finding that TMB between paired primary and metastatic melanoma lesions is highly stable, demonstrates its independency of the time point and location of acquisition. TIL and HLA-ABC status in metastatic lesions of different anatomical sites are highly similar within an individual patient.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-004329","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T13:15:26Z","timestamp":1653311726000},"page":"e004329","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-226X","authenticated-orcid":false,"given":"Mark A J","family":"Gorris","sequence":"first","affiliation":[{"name":"Tumor Immunology, Radboudumc, Nijmegen, The Netherlands"},{"name":"Oncode Institute, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4761-0768","authenticated-orcid":false,"given":"Lieke L","family":"van der Woude","sequence":"additional","affiliation":[{"name":"Tumor Immunology, Radboudumc, Nijmegen, The Netherlands"},{"name":"Oncode Institute, Nijmegen, The Netherlands"},{"name":"Pathology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-1742","authenticated-orcid":false,"given":"Leonie I","family":"Kroeze","sequence":"additional","affiliation":[{"name":"Pathology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-2040","authenticated-orcid":false,"given":"Kalijn","family":"Bol","sequence":"additional","affiliation":[{"name":"Medical Oncology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5223-8406","authenticated-orcid":false,"given":"Kiek","family":"Verrijp","sequence":"additional","affiliation":[{"name":"Oncode Institute, Nijmegen, The Netherlands"},{"name":"Pathology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avital L","family":"Amir","sequence":"additional","affiliation":[{"name":"Pathology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-282X","authenticated-orcid":false,"given":"Jelena","family":"Meek","sequence":"additional","affiliation":[{"name":"Tumor Immunology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0459-9458","authenticated-orcid":false,"given":"Johannes","family":"Textor","sequence":"additional","affiliation":[{"name":"Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands"},{"name":"Data Science Group, Institute for Computing and Information Sciences, Radboud Universiteit, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2366-9212","authenticated-orcid":false,"given":"Carl G","family":"Figdor","sequence":"additional","affiliation":[{"name":"Tumor Immunology, Radboudumc, Nijmegen, The Netherlands"},{"name":"Oncode Institute, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-4040","authenticated-orcid":false,"given":"I Jolanda M","family":"de Vries","sequence":"additional","affiliation":[{"name":"Tumor Immunology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"2025100311034171000_10.5.e004329.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025100311034171000_10.5.e004329.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"2025100311034171000_10.5.e004329.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu441"},{"key":"2025100311034171000_10.5.e004329.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.6018"},{"key":"2025100311034171000_10.5.e004329.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"2025100311034171000_10.5.e004329.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"2025100311034171000_10.5.e004329.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025100311034171000_10.5.e004329.8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9"},{"key":"2025100311034171000_10.5.e004329.9","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.9000","article-title":"Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer","volume":"27","author":"Flaherty","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"2025100311034171000_10.5.e004329.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"2025100311034171000_10.5.e004329.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498"},{"key":"2025100311034171000_10.5.e004329.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095"},{"key":"2025100311034171000_10.5.e004329.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.02.065"},{"key":"2025100311034171000_10.5.e004329.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444."},{"key":"2025100311034171000_10.5.e004329.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"2025100311034171000_10.5.e004329.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006"},{"key":"2025100311034171000_10.5.e004329.17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100311034171000_10.5.e004329.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025100311034171000_10.5.e004329.19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2834"},{"key":"2025100311034171000_10.5.e004329.20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002032"},{"key":"2025100311034171000_10.5.e004329.21","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site \u2014 when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100311034171000_10.5.e004329.22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40364-020-00209-0","article-title":"Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors","volume":"8","author":"Bai","year":"2020","journal-title":"Biomark Res"},{"key":"2025100311034171000_10.5.e004329.23","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"2025100311034171000_10.5.e004329.24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2025100311034171000_10.5.e004329.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1172-6"},{"key":"2025100311034171000_10.5.e004329.26","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e318212dd5a"},{"key":"2025100311034171000_10.5.e004329.27","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-Specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat Commun"},{"key":"2025100311034171000_10.5.e004329.28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3342","article-title":"Mhc proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025100311034171000_10.5.e004329.29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008211"},{"key":"2025100311034171000_10.5.e004329.30","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0070-4"},{"key":"2025100311034171000_10.5.e004329.31","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1200\/jco.2010.28.15_suppl.2555","article-title":"Ctla-4 blockade with ipilimumab increases peripheral CD8+ T cells: correlation with clinical outcomes","volume":"28","author":"Yang","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"2025100311034171000_10.5.e004329.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4797"},{"key":"2025100311034171000_10.5.e004329.33","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.001"},{"key":"2025100311034171000_10.5.e004329.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1771"},{"key":"2025100311034171000_10.5.e004329.35","doi-asserted-by":"crossref","unstructured":"Hamid O , Schmidt H , Nissan A , et al . A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011;9.doi:10.1186\/1479-5876-9-204","DOI":"10.1186\/1479-5876-9-204"},{"key":"2025100311034171000_10.5.e004329.36","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2025100311034171000_10.5.e004329.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0676"},{"key":"2025100311034171000_10.5.e004329.38","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0193"},{"key":"2025100311034171000_10.5.e004329.39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3211"},{"key":"2025100311034171000_10.5.e004329.40","first-page":"83","article-title":"Immune cell infiltration of the primary tumor, not PD-L1 status, is associated with positive response under immune checkpoint blockade in metastatic melanoma","volume":"17","author":"Kumpers","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025100311034171000_10.5.e004329.41","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100311034171000_10.5.e004329.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"2025100311034171000_10.5.e004329.43","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/cncr.32585","article-title":"Considering adjuvant therapy for stage II melanoma","volume":"126","author":"Poklepovic","year":"2020","journal-title":"Cancer"},{"key":"2025100311034171000_10.5.e004329.44","unstructured":"Elder DE , Lazar AJ , Barnhil RL . Who classification of skin tumours."},{"key":"2025100311034171000_10.5.e004329.45","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jmoldx.2020.02.009","article-title":"Evaluation of a hybrid capture-based pan-cancer panel for analysis of treatment Stratifying oncogenic aberrations and processes","volume":"22","author":"Kroeze","year":"2020","journal-title":"J Mol Diagn"},{"key":"2025100311034171000_10.5.e004329.46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701262"},{"key":"2025100311034171000_10.5.e004329.47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02466-x"},{"key":"2025100311034171000_10.5.e004329.48","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2020.11.005","article-title":"Immune cell composition in the endometrium of patients with a complete molar pregnancy: effects on outcome","volume":"160","author":"Hoeijmakers","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2025100311034171000_10.5.e004329.49","doi-asserted-by":"crossref","unstructured":"Sultan S , Gorris MAJ , van der Woude LL . A Segmentation-Free machine learning architecture for immune landscape phenotyping in solid tumors by multichannel imaging. bioRxiv 2021.","DOI":"10.1101\/2021.10.22.464548"},{"key":"2025100311034171000_10.5.e004329.50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0283"},{"key":"2025100311034171000_10.5.e004329.51","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404"},{"key":"2025100311034171000_10.5.e004329.52","doi-asserted-by":"crossref","unstructured":"Stein MK , Pandey M , Xiu J . Tumor mutational burden is site specific in non-small-cell lung cancer and is highest in lung adenocarcinoma brain metastases. Jco Precis Oncol 2019;3.","DOI":"10.1200\/PO.18.00376"},{"key":"2025100311034171000_10.5.e004329.53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.iotech.2019.11.003","article-title":"Tumour mutational burden: primary versus metastatic tissue creates systematic bias","volume":"4","author":"Schnidrig","year":"2019","journal-title":"Immuno-Oncology Technology"},{"key":"2025100311034171000_10.5.e004329.54","doi-asserted-by":"crossref","first-page":"103137","DOI":"10.1016\/j.ebiom.2020.103137","article-title":"Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: a systematic review and meta-analysis","volume":"63","author":"Zou","year":"2021","journal-title":"EBioMedicine"},{"key":"2025100311034171000_10.5.e004329.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.028"},{"key":"2025100311034171000_10.5.e004329.56","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"2025100311034171000_10.5.e004329.57","doi-asserted-by":"publisher","DOI":"10.1101\/gr.165985.113"},{"key":"2025100311034171000_10.5.e004329.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.12.033"},{"key":"2025100311034171000_10.5.e004329.59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1609376113"},{"key":"2025100311034171000_10.5.e004329.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.025"},{"key":"2025100311034171000_10.5.e004329.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.018"},{"key":"2025100311034171000_10.5.e004329.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.073"},{"key":"2025100311034171000_10.5.e004329.63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"2025100311034171000_10.5.e004329.64","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65321-7"},{"key":"2025100311034171000_10.5.e004329.65","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28338"},{"key":"2025100311034171000_10.5.e004329.66","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.498.11.2","article-title":"Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma","volume":"11","author":"Ryschich","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2025100311034171000_10.5.e004329.67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0371"},{"key":"2025100311034171000_10.5.e004329.68","first-page":"88","article-title":"Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors","volume":"158","author":"Tao","year":"2008","journal-title":"Br J Dermatol"},{"key":"2025100311034171000_10.5.e004329.69","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23543"},{"key":"2025100311034171000_10.5.e004329.70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fmed.2019.00027","article-title":"Immune cell infiltration of the primary tumor, not PD-L1 status, is associated with improved response to checkpoint inhibition in metastatic melanoma","volume":"6","author":"K\u00fcmpers","year":"2019","journal-title":"Front Med"},{"key":"2025100311034171000_10.5.e004329.71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00262-017-2072-1","article-title":"Tumor-Infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy","volume":"67","author":"Balatoni","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2025100311034171000_10.5.e004329.72","doi-asserted-by":"crossref","unstructured":"Harder N , Sch\u00f6nmeyer R , Nekolla K , et al . Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. Sci Rep 2019;9.doi:10.1038\/s41598-019-43525-8","DOI":"10.1038\/s41598-019-43525-8"},{"key":"2025100311034171000_10.5.e004329.73","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1405206","article-title":"Pd-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab","volume":"7","author":"Madonna","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100311034171000_10.5.e004329.74","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad6352","article-title":"The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis","volume":"8","author":"Mlecnik","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025100311034171000_10.5.e004329.75","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000161"},{"key":"2025100311034171000_10.5.e004329.76","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101406","article-title":"Tertiary lymphoid structures and B cells: clinical impact and therapeutic modulation in cancer","volume":"48","author":"Saut\u00e8s-Fridman","year":"2020","journal-title":"Semin Immunol"},{"key":"2025100311034171000_10.5.e004329.77","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-004329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:03:54Z","timestamp":1759514634000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":77,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,12]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/jitc-2021-004329"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-004329","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}